Alpha Teknova, Inc. reported a revenue of $40.5 million for the fiscal year ending December 31, 2025, marking a 7.4% increase from $37.7 million in 2024. The company's gross profit rose significantly to $13.4 million, up 85.9% from $7.2 million the previous year, primarily due to improved manufacturing efficiencies and a reduction in non-recurring charges related to inventory disposal. Despite the revenue growth, Alpha Teknova incurred a net loss of $17.3 million, a decrease from a loss of $26.7 million in 2024, reflecting a 35.5% improvement in operating performance.
The company experienced notable changes in its operational metrics, with Lab Essentials revenue increasing by 7.5% to $31.0 million, while Clinical Solutions revenue rose by 7.8% to $7.7 million. The growth in both categories was attributed to an increase in customer counts, although average revenue per customer declined. Geographically, 94.4% of revenue was generated from U.S. customers, with international sales growing to $2.3 million, representing 5.6% of total revenue.
Strategically, Alpha Teknova entered into a Second Amended and Restated Credit Agreement in March 2025, securing loan commitments of up to $28.245 million. This agreement includes minimum revenue and cash requirements, which the company met as of December 31, 2025. The company also plans to expand its geographic reach, particularly in Europe, to tap into markets that require custom formulations with short turnaround times.
Operationally, Alpha Teknova's workforce consisted of 158 full-time employees as of December 31, 2025. The company aims to enhance its manufacturing capacity and efficiency through investments in infrastructure and automation. The outlook for the company remains cautiously optimistic, with expectations of continued revenue growth driven by demand for custom reagents in emerging therapeutic modalities, including cell and gene therapies and mRNA vaccines. However, the company acknowledges potential risks from economic conditions, including inflation and supply chain disruptions, which could impact customer demand and operational costs.
About Alpha Teknova, Inc.
Alpha Teknova, Inc. manufactures custom chemical reagents and media critical for life sciences research, drug development, and molecular diagnostics. Serving pharmaceutical, biotechnology, diagnostics, and academic customers, it offers pre-poured media plates, cell culture media, and molecular biology reagents. Its adaptable manufacturing processes enable rapid, scalable production of research-use and GMP-grade products, supporting customers from discovery through commercialization with high quality, fast turnaround, and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.